Results 61 to 70 of about 25,648 (169)

Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. [PDF]

, 2016
Protein-protein interactions (PPIs) are of pivotal importance in the regulation of biological systems and are consequently implicated in the development of disease states.
A Ciulli, A Degterev, A Oberstein, A Patel, A Patel, A Shaginian, A Turnbull, A Winter, AA Bogan, AA Lugovskoy, AB Mahon, AC Braisted, AD Morley, AF Donnell, AG Coyne, AJ Souers, AL Jochim, AM Petros, AM Petros, Andrew R. Bayly, AP Higueruelo, AR Bayly, AV Follis, B Ku, B Lehner, B Ma, B Padmanabhan, BC Raimundo, BE Sleebs, BL Grasberger, C Tse, C Zhuang, CA Lepre, CD Thanos, CG Wilson, CH Arrowsmith, CH Kenny, Chris Abell, CQ Wei, CQ Wei, D Cox, D Grimme, D Marcotte, D Rognan, D Seebach, D Szklarczyk, DA Erlanson, DC Fry, DE Scott, DE Scott, DI Hammoudeh, DJ Craik, DJ Huggins, DK Johnson, Duncan E. Scott, EF Lee, EF Lee, EF Lee, F Christ, F Cossu, F Falchi, FB Sheinerman, FP Davis, G Wang, G Zimmermann, GR Bickerton, H Jhoti, H Jubb, H Karatas, H Sun, H Wu, H Yin, H Zhou, HL Perez, HP Sun, HY Sun, I Monfardini, I Navratilova, I Van Molle, IJ Enyedy, J Hyde, J Liu, JA Kritzer, JA Wells, JB Baell, JC Fuller, JD Sadowsky, JG Allen, JL Wang, JM Davis, John Skidmore, JW Huang, JW Tilley, K Sauve, KI Tong, L Chen, L Hu, L Pellegrini, LD Walensky, LD Walensky, LK Henchey, LM Meireles, LT Vassilev, M Bruncko, M Rickert, M Sattler, M Vogler, M Whittaker, MC Lo, MC Smith, MD Wendt, MJ Basse, MJ de Vega, ML Stewart, MR Arkin, MR Arkin, N Sugaya, O Ichihara, O Keskin, O Keskin, O Mirguet, P Chakrabarti, P Filippakopoulos, P Filippakopoulos, P Mukherjee, P Sledz, P Walter, PJ Hajduk, PJ Hajduk, PJ Real, PW White, Q Cai, Q Chu, QC Zhang, R Hancock, R Hancock, RF Kester, RJ Bienstock, RJ Robb, S Barelier, S Ducki, S Ferrari, S Fletcher, S Fletcher, S Jones, S Miller, SC Lo, SD Furdas, SM Biros, SM Srinivasula, SP Brown, T Clackson, TA Larsen, TG Davies, TJ Blackburn, TK Oost, TL Blundell, TL Blundell, TS Peat, VS Rao, W Antuch, WA Loughlin, WB Turnbull, X Morelli, XQ Liu, Y Chen, Y Huang, Y Tanaka, Y Zhao, YS Tan, Z Hu, ZY Jiang   +171 more
core   +2 more sources

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia

Nature Communications, 2018
BCL2-inhibitor venetoclax is used to treat relapsed/refractory chronic lymphocytic leukemia (CLL). Here, the authors show the clonal dynamics towards venetoclax resistance by performing whole-exome sequencing of 8 CLL patients undergoing venetoclax ...
Carmen D. Herling, Nima Abedpour, Jonathan Weiss, Anna Schmitt, Ron Daniel Jachimowicz, Olaf Merkel, Maria Cartolano, Sebastian Oberbeck, Petra Mayer, Valeska Berg, Daniel Thomalla, Nadine Kutsch, Marius Stiefelhagen, Paula Cramer, Clemens-Martin Wendtner, Thorsten Persigehl, Andreas Saleh, Janine Altmüller, Peter Nürnberg, Christian Pallasch, Viktor Achter, Ulrich Lang, Barbara Eichhorst, Roberta Castiglione, Stephan C. Schäfer, Reinhard Büttner, Karl-Anton Kreuzer, Hans Christian Reinhardt, Michael Hallek, Lukas P. Frenzel, Martin Peifer   +30 more
doaj   +1 more source

Hot-spot analysis for drug discovery targeting protein-protein interactions [PDF]

, 2018
Introduction: Protein-protein interactions are important for biological processes and pathological situations, and are attractive targets for drug discovery. However, rational drug design targeting protein-protein interactions is still highly challenging.
Fernández-Recio, Juan, Rosell, Mireia
core   +2 more sources

Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: Case report and exploration of possible mechanisms

Heliyon
Venetoclax, a selective BCL-2 inhibitor, has shown superior efficacy in the treatment of AML. Nevertheless, some AML patients with AML1-ETO respond poorly to venetoclax treatment.
Man Li, Xiawan Yang, Yaonan Hong, Qi Liu, Yingying Shen, Tonglin Hu, Yiping Shen, Guoyin Kai, Dijiong Wu   +8 more
doaj   +1 more source

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial [PDF]

, 2019
Aprospective trial conducted in the period 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (RHDS) versus conventional chemotherapy with rituximab (CHOP-R) as firstline therapy in 134 high-risk follicular ...
Angrilli, F., Barbui, A. M., Benedetti, F., Billio, A., Boccomini, C., Bruna, R., Castellino, C., Ciceri, F., Corradini, P., Devizzi, L., Di Raimondo, F., Dondi, A., Gini, G., Gueli, A., Ladetto, M., Lanza, F., Liberati, A. M., Mantoan, B., Massimo Gianni, A., Musso, M., Narni, F., Parvis, G., Passera, R., Patti, C., Perrone, T., Pulsoni, A., Rambaldi, A., Rossini, F., Rota-Scalabrini, D., Semenzato, G., Stelitano, C., Tarella, C., Tucci, A., Zallio, F., Zoli, V.   +34 more
core   +4 more sources

Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway

Advanced Science
Relapsed and refractory multiple myeloma (RRMM) remains the leading cause of MM mortality. FOXM1 is strongly associated with RRMM, making it a compelling therapeutic target.
Zhi Wen, Yidan Wang, Kathryn C. Fox, Adam M. Bissonnette, Luke F. Moat, Terrie E. Kitchner, Kelsey Springstroh, Sung Hoon Kim, Dagna S. Sheerar, Patcharon Tanawattanacharoen, Chady A. Leon, Seth O. Fagbemi, John A. Katzenellenbogen, Scott J. Hebbring, Benita S. Katzenellenbogen, Siegfried Janz, Adedayo A. Onitilo   +16 more
doaj   +1 more source

Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia

Haematologica
The treatment of blast phase chronic myeloid leukemia (bpCML) remains a challenge due at least in part to drug resistance of leukemia stem cells (LSCs).
Mohd Minhajuddin, Amanda Winters, Haobin Ye, Shanshan Pei, Brett Stevens, Austin Gillen, Krysta Engel, Stephanie Gipson, Monica Ransom, Maria Amaya, Anagha Inguva, Maura Gasparetto, Mark J. Althoff, Regan Miller, Ian Shelton, Hunter Tolison, Anna Krug, Rachel Culp-Hill, Angelo D’Alessandro, Daniel W Sherbenou, Daniel A. Pollyea, Clayton Smith, Craig T Jordan   +22 more
doaj   +1 more source

Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW. [PDF]

, 2017
Purpose: B-cell lymphomas must acquire resistance to apoptosis during their development. We recently discovered BCLW, an antiapoptotic BCL2 family member thought only to contribute to spermatogenesis, was overexpressed in diffuse large B-cell lymphoma ...
Adams, Clare M., Eischen, Christine M., Gong, MD, Jerald Z., Mitra, Ramkrishna   +3 more
core   +1 more source

P042 | PU.1 as master regulator of acute myeloid leukemia venetoclax resistance

Haematologica
Introduction. Venetoclax-based therapies have improved outcomes in acute myeloid leukemia (AML), especially in elderly or unfit patients. However, resistance remains a major limitation.
Alessandro Ferrando
doaj  

Remission rate, toxicity and pharmacokinetics of venetoclax-based induction regimens in untreated pediatric acute myeloid leukemia

npj Precision Oncology
The efficacy and safety of venetoclax in newly diagnosed pediatric acute myeloid leukemia (AML) are not well-established as they are in adults. Children newly diagnosed with AML were recommended for induction therapy with venetoclax and chemotherapy or ...
Xiaojia Wen, Yu Lu, Yanming Li, Peijing Qi, Ying Wu, Jiaole Yu, Ruidong Zhang, Qian Huang, Pengli Huang, Bei Hou, Jie Yang, Mengjia Liu, Huiqing Liu, Hongqiao Li, Ning Sun, Yanni Zhang, Yuanyuan Zhang, Wei Lin, Jia Fan, Yan Liu, Huyong Zheng   +20 more
doaj   +1 more source